Publications

Journal Article Ppublish 9 citations
Electronic publication date
February 12, 2024

View on Pubmed.gov 38271745 | View on doi.org 10.1016/j.ejca....

First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.

Search for publications in this journal Eur J Cancer

Abstract

BACKGROUND

The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METΔ14ex) remains controversial.

MATERIALS AND METHODS

110 consecutive METΔ14ex NSCLC patients receiving first-line chemotherapy (CHT) and/or immunotherapy (IO) in 10 German centers between 2016-2022 were analyzed.

RESULTS

Combined CHT-IO was given to 35/110 (32%) patients, IO alone to 43/110 (39%), and CHT to 32/110 (29%) upfront. Compared to CHT, CHT-IO showed longer progression-free survival (median PFS 6 vs. 2.5 months, p = 0.004), more objective responses (ORR 49% vs. 28%, p = 0.086) and numerically longer overall survival (OS 16 vs. 10 months, p = 0.240). For IO monotherapy, OS (14 vs. 16 months) and duration of response (26 vs. 22 months) were comparable to those of CHT-IO. Primary progressive disease (PD) was more frequent with IO compared to CHT-IO (13/43 vs. 3/35, p = 0.018), particularly for never-smokers (p = 0.041). Higher PD-L1 TPS were not associated with better IO outcomes, but TP53 mutated tumors showed numerically improved ORR (56% vs. 32%, p = 0.088) and PFS (6 vs. 3 months, p = 0.160), as well as longer OS in multivariable analysis (HR=0.54, p = 0.034) compared to their wild-type counterparts. Any second-line treatment was administered to 35/75 (47%) patients, with longer survival for capmatinib or tepotinib compared to crizotinib (PFS 10 vs. 3 months, p = 0.013; OS 16 vs. 13 months, p = 0.270).

CONCLUSION

CHT-IO is superior to CHT, and IO alone also effective for METΔ14ex NSCLC, especially in the presence of TP53 mutations and independent of PD-L1 expression, but never-smokers are at higher risk of primary PD.

References

No references provided.

Cited by 9 citations (total)

Journal Article Review

Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.

Electronic publication date June 17, 2025

Search for publications in this journal Cancer Metastasis Rev

Bassel Alsaed [...] Heidi M Haikala et al.

The two most common and mutually exclusive driver mutations in non-small cell lung cancer affect EGFR and KRAS oncogenes. While...

Journal Article

Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.

Electronic publication date August 6, 2025

Search for publications in this journal JCO Precis Oncol

Jonas Kulhavy [...] Horst-Dieter Hummel et al.

PURPOSE

Epidermal growth factor receptor (EGFR) mutations are a main actionable driver in non-small cell lung cancer (NSCLC). However, the clinical...

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JK: speaker’s honoraria from BMS, AstraZeneca and Pfizer, travel grants from Takeda, advisory board honoraria from Takeda, Roche and AstraZeneca. DM: advisory board/lecture fees from AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Novartis, Roche, Sanofi and Takeda. DiKa: advisory boards/speaker´s honoraria from BMS, Boehringer-Ingelheim, MSD, Roche, Janssen, Pfizer, AstraZeneca; support for attending meetings from Novartis, Boehringer-Ingelheim. MH: advisory board, speaker’s honoraria and travel grants from Boehringer-Ingelheim. BH: advisory board/lecture fees from AstraZeneca, Boehringer Ingelheim, BMS, MSD, Roche, Pfizer. MF: grants from AstraZeneca, BMS, MSD, and Roche; consulting fees from AstraZeneca, MSD, Roche, BMS; speaker´s honoraria from AstraZeneca, MSD, Roche, BMS. MK: speaker’s honoraria and travel grants from Veracyte Inc. AV: speaker’s honoraria from AstraZeneca. MA: speaker’s honoraria from Boehringer Ingelheim. CG: advisory board/lecture fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Takeda, MSD, Novartis, Pfizer, Roche, AbbVie, Tesaro/GSK and Blueprints Medicines. AT: consulting fees from Boehringer Ingelheim, Daiichi, Astra Zeneca, Roche, Pfizer, BMS, MSD, Sanofi, Lilly, Novartis; speaker’s honoraria from Boehringer Ingelheim, Daiichi, Astra Zeneca, Roche, Pfizer, BMS, MSD, Sanofi, Lilly, Novartis; travel grants from Sanofi, Janssen, Daiichi; BMS, MSD, AstraZeneca. MR: advisory board/lecture fees from Amgen, AstraZeneca, BMS, Boehringer, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Samsung. NF: grants from Roche, consulting fees from AbbVie, Amgen, AstraZeneca, BeiGene, Berlinchemie, Boehringer Ingelheim, Bristol Myers&Squibb, Lilly, Merck Sharp&Dohme, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda; support for attending meetings from Amgen, AstraZeneca, BMS, Janssen, Lilly, Takeda. AS: advisory board honoraria from BMS, AstraZeneca, ThermoFisher, Novartis, speaker’s honoraria from BMS, Illumina, AstraZeneca, Novartis, ThermoFisher, MSD, Roche, and research funding from Chugai and BMS. MT: research funding from AstraZeneca, BMS, Merck, Roche, Takeda; speaker’s honoraria from AstraZeneca, Beigene, Novartis, Eli Lilly, BMS, MSD, Roche, Celgene, Takeda, AbbVie, Boehringer Ingelheim, Pfizer, Eli Lilly, MSD, Takeda, Pfizer, Chugai, Daiichi Sankyo, GlaxoSmithKline, Janssen Oncology, Merck, Sanofi and travel grants from AstraZeneca, BMS, MSD, Novartis, Daiichi Sankyo, Janssen Oncology, Lilly, Merck, Pfizer, Roche, Sanofi, Takeda, Boehringer Ingelheim. PC: research funding from AstraZeneca, Amgen, Boehringer Ingelheim, Novartis, Roche, and Takeda, speaker’s honoraria from AstraZeneca, Janssen, Novartis, Roche, Pfizer, Thermo Fisher, Takeda, support for attending meetings from AstraZeneca, Eli Lilly, Daiichi Sankyo, Gilead, Novartis, Pfizer, Takeda, and personal fees for participating to advisory boards from AstraZeneca, Boehringer Ingelheim, Chugai, Pfizer, Novartis, MSD, Takeda and Roche, all outside the submitted work. All other authors have no conflicts of interest to declare.

MeSH

Specialties

Substances

Copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.